Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2202 • ACR Convergence 2023
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers
Richard B. Warren¹, Mark Lebwohl², Shinichi Imafuku³, Jerry Bagel⁴, April W. Armstrong⁵, Thierry Passeron⁶, Misti Linaberry⁷, Kim Hoyt⁷, Andrew Napoli⁷, Renata M. Kisa⁷, Diamant Thaçi⁸ and Andrew Blauvelt⁹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Fukuoka University Faculty of Medicine, Fukuoka, Japan, ⁴Psoriasis Treatment Center of New Jersey, East Windsor, NJ, ⁵Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁶Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁹Oregon Medical Research Center, Portland, OR
Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults with plaque psoriasis; it…
Abstract Number: 2272 • ACR Convergence 2023
Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States
Rashmi Dhital¹, Ioannis Karageorgiou², Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²William Beaumont University Hospital, Troy, MI, ³William Beaumont University Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently visit the emergency department (ED) due to the complex disease course. Previous research highlights infection and pain…
Abstract Number: 2290 • ACR Convergence 2023
Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model
Chrisanna Dobrowolski¹, Juan Pablo Diaz Martinez², Michelle Barraclough³, Roberta Kretzmann⁴, Sherief Marzouk⁴, Kathleen Bingham³, Lesley Ruttan⁵, Dorcas Beaton⁶, Joan Wither³, Carmela Tartaglia⁷, Patti Katz⁸, Mahta Kakvan⁹, Nicole Anderson¹⁰, Dennisse Bonilla³ and Zahi Touma⁴, ¹Icahn School of Medicine at Mount Sinai Hospital, New York, NY, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Institute for Work & Health, Toronto, ON, Canada, ⁷Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸University of California San Francisco, San Rafael, CA, ⁹University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is a common and often deleterious manifestation of systemic lupus erythematosus (SLE). CD is usually operationalized on the American College of…
Abstract Number: 2306 • ACR Convergence 2023
Changes in Rheumatology Disease Measures After Initiation of Belimumab Treatment in Patients with Systemic Lupus Erythematosus
Karen Worley¹, Christopher Bell², Bernard Rubin³, Guillaume Germain⁴, François Laliberté⁴, Sean MacKnight⁴, Ana Urosevic⁴ and Mei Sheng Duh⁵, ¹GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ²GlaxoSmithKline, US Value Evidence and Outcomes, Durham, NC, ³GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁴Groupe d’analyse, Ltée, Montreal, QC, Canada, ⁵Analysis Group, Boston, MA
Background/Purpose: Real-world benefits of belimumab (BL) in patients with SLE have been shown using SLE-specific measures.1,2 As SLE disease activity measurement is challenging,3 assessment of…
Abstract Number: 2322 • ACR Convergence 2023
Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State
Yasmin Nariman¹, Juan Pablo Diaz Martinez², Kathleen Bingham¹, Patti Katz³ and Zahi Touma⁴, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³University of California San Francisco, San Rafael, CA, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression is one of the most common neuropsychiatric disorders in patients with SLE. The Centre for Epidemiologic Studies Depression Scale (CES-D) has been used…
Abstract Number: 2341 • ACR Convergence 2023
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Javier Loricera³, Clara Moriano Morales⁴, Carmen Lasa⁵, Vanesa Calvo Río⁶, Javier Narvaez⁷, Pablo Ignacio Navarro Guerra⁸, Ivette Casafont-Sole⁹, Judit Font Urgelles¹⁰, Adela Gallego¹¹, Irene Carrión-Barberà¹², Patricia Quiroga¹³, Santos Castañeda¹³, Angel Garcia-Aparicio¹⁴, Joaquin Maria Belzunegui Otano¹⁵, Juan Ramon De Dios¹⁶, Marta López¹⁷, Samuel Hernandez¹⁸, Sergi Heredia Martin¹⁹, Aaron Fariñas²⁰, Francisco Navarro²¹, Jorge Juan Fragio²², Carmen Escudero²³, Rafaela Ortega Castro²⁴, Leticia del Olmo Perez²⁵, Valvanera Pinillos²⁶, Eztizen Labrador²⁶, Mamen Ortega²⁷, Patricia Castro Pérez²⁷, Juan Maria Blanco-Madrigal²⁸, Marcos Paulino²⁹, María Ángeles Matías³⁰, Enrique Calvo-Aranda³¹, Cilia Peralta³², Silvia García³³, Jordi Camins-Fàbregas³⁴, Marta Garijo Bufort³⁵, Dolores Fabregas³⁶, Ana Urruticoechea³⁷, Miguel Medina Malone³⁸, Piter Jose Cossio Jimenez³⁹, Eva Perez-Pampin⁴⁰, Blanca Varas de Dios⁴¹, Carlos Vazquez Galeano⁴², Nuria Vegas Revenga⁴³, Olga Rusinovich⁴⁴, Emilio Giner-Serret⁴⁵, Jose Ramón lamúa⁴⁶ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario de León, León, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Hospital Universitario de Toledo, Toledo, Spain, ¹⁵University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Arava, Pamplona, Spain, ¹⁸Hospital Universitario Son Llatzer, Palma de Mallorca, Spain, ¹⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁰Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²¹Doctor. Rheumatology, Alicante, Spain, ²²Hospital General Universitario Valencia, Valencia, Spain, ²³Hospital Universitario de Valme, Sevilla, Spain, ²⁴Hospital Reina Sofía, Cordoba, Spain, ²⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ²⁶Hospital Universitario San Pedro, Logroño, Spain, ²⁷Hospital Universitario de Getafe, Getafe, Spain, ²⁸Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ²⁹Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ³⁰Hospital Universitario Infanta Leonor/Rheumatology Department, Madrid, Spain, ³¹Hospital Universitario Infanta Leonor, Madrid, Spain, ³²Hospital Clínico Lozano Blesa, Zaragoza, Spain, ³³Hospital Parc Taulí, Sabadell, Spain, ³⁴Hospital General de Granollers, Granollers, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital de Barbastro, Barbastro, Spain, ³⁷Hospital Can Misses, Ibiza, Spain, ³⁸Hospital Calahorra, Calahorra, Spain, ³⁹HOSPITAL REINA SOFIA, Tudela, Spain, ⁴⁰Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁴¹Santa Cristina Universitary Hospital, Madrid, Spain, ⁴²ZARAGOZA, Madrid, Spain, ⁴³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴⁴Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ⁴⁵Hospital Royo Villanova, Teruel, Spain, ⁴⁶Hospital Universitario del Henares, Alcalá de Henares, Spain
Background/Purpose: Belimumab (BLM) is a monoclonal antibody that inhibits B-lymphocyte stimulating factor (BlyS), approved in 2011 as a treatment for systemic lupus erythematosus (SLE). We…
Abstract Number: 2449 • ACR Convergence 2023
Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study
Laura Plantinga¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Courtney Hoge¹, Bradley Pearce¹, Cristina Drenkard¹ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: Studies of objectively measured cognitive dysfunction in SLE are often limited by small sample size, limited generalizability, and lack of diversity. We sought to…
Abstract Number: 2515 • ACR Convergence 2023
Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura⁵ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc).…
Abstract Number: PP03 • ACR Convergence 2023
Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime
Amanda Greene, Los Angeles, CA
Background/Purpose: In 1983, over forty years ago, I was diagnosed with Systemic Lupus Erythematosus (SLE). I was immediately prescribed high dose corticosteroids. My body and…
Abstract Number: 0060 • ACR Convergence 2023
Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity
Ting Wang¹, Philip Pemberton² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Redd Pharmaceuticals, Belmont, CA
Background/Purpose: Autoantibody-antigen complex-driven formation of neutrophil extracellular traps (NETs) is a major contributing factor to the pathophysiology and clinical manifestations of many different autoimmune diseases…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…
Abstract Number: 0261 • ACR Convergence 2023
Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results
April W. Armstrong¹, Mark Lebwohl², Richard B. Warren³, Howard Sofen⁴, Shinichi Imafuku⁵, Mamitaro Ohtsuki⁶, Lynda Spelman⁷, Thierry Passeron⁸, Kim A Papp⁹, Renata M. Kisa¹⁰, Victoria Berger¹⁰, Eleni Vritzali¹¹, Kim Hoyt¹⁰, Matthew J. Colombo¹⁰, Subhashis Banerjee¹⁰, Bruce Strober¹², Diamant Thaçi¹³ and Andrew Blauvelt¹⁴, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, CA, ⁵Fukuoka University Faculty of Medicine, Fukuoka, Japan, ⁶Jichi Medical University, Tochigi, Japan, ⁷Veracity Clinical Research, Brisbane, Australia, ⁸Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁹Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Bristol Myers Squibb, Sissach, Switzerland, ¹²Yale University, New Haven, CT, ¹³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹⁴Oregon Medical Research Center, Portland, OR
Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults plaque psoriasis. Deucravacitinib was…
Abstract Number: 0550 • ACR Convergence 2023
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…
Abstract Number: 0567 • ACR Convergence 2023
N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study
Karim Sacre¹, Evelyne Vinet², Christian Pineau², Arielle Mendel³, Fares Kalache³, Louis Pierre Grenier³, Thao Huynh³ and Sasha Bernatsky⁴, ¹Université Paris Cité, Paris, France, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Cardiovascular (CV) disease represents the leading cause of death in SLE. Traditional risk factors are less accurate at identifying cardiovascular risk in SLE than…
Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Tobias Schmidt¹, Christina Brock², Jesper Fleischer³, Søren Jacobsen¹ and Amanda Hempel Zinglersen¹, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg, Denmark, ³Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].